EchoSolv AS vs AVIEW

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

EchoSolv AS

by Echo IQ

AVIEW

by Coreline Soft Co.

AI Verdict

EchoSolv AS is specifically designed for the detection of severe aortic stenosis using echocardiogram measurements, offering targeted clinical decision support. In contrast, AVIEW provides a broader AI platform for analyzing CT scans, focusing on lung cancer, COPD, and coronary artery calcification. While both tools leverage AI in cardiology, they cater to distinct diagnostic needs and utilize different imaging modalities.

Choose EchoSolv AS if…

Choose EchoSolv AS if your primary need is rapid, highly accurate AI-powered clinical decision support specifically for identifying patients at risk of severe aortic stenosis from echocardiogram measurements. This tool is ideal for cardiology departments seeking to enhance efficiency and consistency in sAS detection, providing a second reader function and integrating seamlessly with PACS without requiring EMR integration.

View EchoSolv AS →

Choose AVIEW if…

Choose AVIEW if you require a comprehensive AI platform for analyzing CT scans across multiple thoracic conditions, including early detection and monitoring of lung cancer, COPD, and coronary artery calcification. This solution is best suited for radiology and pulmonology departments looking for detailed quantification, 3D visualizations, and workflow automation to streamline diagnostics and follow-up for a broader range of CT-based assessments.

View AVIEW →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	EchoSolv AS	AVIEW
Pricing	Unknown	Subscription; one-off payment
Deployment	Cloud-based	Cloud-based; Hybrid solution; Locally on dedicated hardware; Locally virtualized (virtual machine, Docker)
BAA Available	Yes AI-estimated	Unknown
FDA Status	Cleared AI-estimated	Cleared AI-estimated
HIPAA	Yes AI-estimated	Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

EchoSolv AS

EchoSolv AS emphasizes a 'simple' integration that does not require EMR integration, focusing on PACS integration and 'ultra-fast risk detection (under 3 seconds)'. This suggests a highly streamlined and focused user experience with minimal disruption to existing workflows, making it potentially easier to adopt and use immediately.

Clinical Value

AVIEW

While EchoSolv AS provides highly accurate, FDA-cleared AI for a critical specific condition (severe aortic stenosis), AVIEW offers a broader, FDA-cleared platform for the early detection, diagnosis, and monitoring of multiple significant conditions, including lung cancer, COPD, and coronary artery calcification from CT scans. This comprehensive scope across several specialties provides a wider range of clinical utility and potential impact for a healthcare institution.

Pricing & Value

AVIEW

AVIEW provides transparent pricing models, including subscription and one-off payment options, with details on factors like the number of installations and users. In contrast, no public pricing information was readily available for EchoSolv AS, requiring direct contact for details. This transparency from Tool B offers greater clarity and predictability for potential buyers.

Enterprise Readiness

AVIEW

Both tools are HIPAA compliant and FDA cleared. However, AVIEW offers superior deployment flexibility, supporting cloud-based, hybrid, local dedicated hardware, and locally virtualized options. This wide range of deployment choices makes it more adaptable to diverse enterprise IT infrastructures and security policies compared to EchoSolv AS's cloud-based deployment.

Innovation

AVIEW

EchoSolv AS demonstrates innovation in its specific 'measurement-based AI' approach that 'does not use LVOT measurements' for severe AS detection. However, AVIEW showcases broader innovation through its comprehensive suite of AI tools for multiple conditions, including advanced features like automated segmentation, 3D visualizations, nodule matching for serial scans, and Interstitial Lung Disease (ILD) pattern analysis, pushing the boundaries of automated diagnostic imaging across several modalities.

Support & Docs

Tie

Based on the provided structured facts and web searches, neither EchoSolv AS nor AVIEW offers readily accessible public information regarding their specific support channels, documentation availability, or service level agreements. Without this information, it is not possible to differentiate between the two tools on this dimension.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	EchoSolv AS	AVIEW
Name	EchoSolv AS	AVIEW
Company	Echo IQ	Coreline Soft Co.
Primary Focus	Analyzes echocardiograms to identify patients at risk for severe aortic stenosis.	Offers comprehensive solutions for early detection, diagnosis, and monitoring of lung cancer, COPD, and coronary artery calcification from CT scans.
Key Cardiology AI Capabilities	AI-powered clinical decision support for severe aortic stenosis probability; Consistent severe AS probability and guideline check from measurements; Second reader support; Measurement-based AI (analyzes numerical measurements, not images).	Coronary artery calcium (CAC) scoring (Agatston, volume, mass score, risk stratification); Automated segmentation of coronary arteries.
Other Key AI Capabilities	Not specified	AI-powered lung nodule detection and characterization; Emphysema quantification and low attenuation area (LAA) analysis; Interstitial Lung Disease (ILD) pattern analysis.
Workflow Integration	Designed to fit existing workflows (no EMR integration required, integrates with PACS).	Workflow automation and integration with PACS/RIS/CIS.

Videos

Demos, reviews, and walkthroughs featuring EchoSolv AS and AVIEW.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

What are the primary clinical applications for each AI tool?

EchoSolv AS is specifically designed to identify patients at risk for severe aortic stenosis (sAS) by analyzing echocardiograms. AVIEW offers comprehensive solutions for the early detection, diagnosis, and monitoring of lung cancer, COPD, and coronary artery calcification from CT scans, also including interstitial lung disease (ILD) pattern analysis.

What type of imaging data does each tool analyze, and how does their AI function?

EchoSolv AS analyzes numerical measurements from echocardiograms to determine the probability of severe aortic stenosis, rather than processing images directly. AVIEW processes CT scans to provide AI-driven diagnostic solutions, including lung nodule detection, emphysema quantification, and coronary artery calcium scoring.

How do these tools integrate into existing clinical workflows?

EchoSolv AS is designed to fit existing workflows and integrates with PACS, without requiring EMR integration. AVIEW also offers workflow automation and integration with PACS/RIS/CIS, including features for follow-up registration and nodule matching for serial CT scans.

Which medical specialties are primarily targeted by each AI solution?

EchoSolv AS is primarily aimed at Cardiology and Cardiothoracic Surgery. AVIEW supports a broader range of specialties, including Cardiology, Pulmonology, and Radiology.

What specific diagnostic insights and reports do these tools generate?

EchoSolv AS provides consistent severe AS probability and guideline checks from measurements, offering second reader support for prioritizing studies. AVIEW generates detailed outputs such as lung nodule detection and characterization (size, volume, type, Lung-RADS score), emphysema quantification, coronary artery calcium scoring, automated segmentations, and comprehensive PDF reports.